Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Oct 14;9(19):4924-4935.
doi: 10.1182/bloodadvances.2025016661.

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

Antonio Gutierrez  1 , Izaskun Zeberio  2 , Francisco Javier Peñalver  3 , Pilar Martinez-Barranco  3 , Sandra Perez  1 , Daniel Morillo  4 , Xabier Martin  5 , Concepcion Nicolas  6 , Ainara Ferrero  7 , Ana Jimenez-Ubieto  8 , Mariana Bastos-Oreiro  9 , Julio Davila-Valls  10 , Maria Victoria Calle  11 , María Perez  12 , Guillermo Rodriguez  13 , Aranzazu Alonso  14 , Ana Garcia-Noblejas  15 , Diana Sanchez Argüello  16 , Teresa Knight  17 , Ángeles Fernandez  18 , Javier Lopez  19 , Jaime Perez De Oteyza  20 , Sonia González de Villambrosia  21 , Elena Perez  22 , Alejandro Marin  23 , Maria Belen Navarro  24 , Ruben Fernandez  25 , Pilar Gomez  26 , José Antonio Hueso  27 , Maria Jesus Peñarrubia Ponce  28 , Pilar Bravo  29 , Daniel Garcia-Belmonte  30 , Haridian De La Nuez  31 , Sara Nistal  32 , Pau Abrisqueta  33 , Fernanda Ibañez  34 , Luis Palomera  35 , Eva Donato  36 , Andrea Provencio  37 , Maria Stefania Infante  38 , Eva Gonzalez-Barca  39
Affiliations
Observational Study

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

Antonio Gutierrez et al. Blood Adv. .

Abstract

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, although real-world evidence studies have not consistently confirmed these results. We aimed to describe real-world outcomes of R/R DLBCL treated with T/L in Spain. A total of 99 patients received at least 1 dose of tafasitamab (intent-to-treat [ITT] cohort), with 83 completing at least 1 full cycle of T/L (efficacy cohort). Respectively for ITT and efficacy cohorts, at a median follow-up of 19.2 and 21.6 months, the overall response rate was 51% and 61% (complete response [CR], 35% and 42%). Median duration of response was not reached, and patients achieving a CR had excellent outcomes. The median progression-free survival (PFS) was 4.9 and 10.9 months, and overall survival (OS) was 12.2 and 21.8 months, respectively for both ITT and efficacy cohorts. Neither age nor cumulative illness rating score influenced survival. Better PFS was obtained in first/second relapse but only poor Eastern Cooperative Oncology Group performance status 2 to 4, double-hit lymphoma, and those with refractory/progressing disease after the previous therapy, were independently associated with worse PFS. Treatment was generally well tolerated, with manageable toxicity. Relative dose intensity of lenalidomide significantly affected response, PFS, and OS. In summary, T/L is both well tolerated and effective, irrespective of age or comorbidities. Our findings provide valuable insights into the real-world application of T/L and reinforce its role as a key treatment option for patients with R/R DLBCL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.G. has received research funding and honoraria from Janssen, AbbVie, Roche, AstraZeneca, Incyte, Takeda, Lilly, and BeiGene; M.B.-O. has received research funding and honoraria from Incyte, Roche, AbbVie, and Kite; P.A. has received honoraria from BeiGene, Janssen, Roche, Bristol Myers Squibb, AbbVie, Incyte, Gilead, and AstraZeneca. I.Z. and E.G.-B. disclose honoraria from Incyte. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
General efficay plots. DOR in the efficacy cohort (A) and ITT cohort (D); OS in the efficacy cohort (B) and ITT cohort (E); and PFS in the efficacy cohort (C) and ITT cohort (F).
Figure 2.
Figure 2.
Impact of RDI for lenalidomide. (A) DOR, and (B) PFS according to RDI for lenalidomide in the efficacy and (C) ITT cohorts. CR, complete response; PR, partial response; SD, stable disease; PD, progression of disease.
Figure 3.
Figure 3.
Impact of RDI for lenalidomide. DOR (A), and PFS according to RDI for lenalidomide in the efficacy (B) and ITT (C) cohorts.
See this image and copyright information in PMC

References

    1. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045. - PMC - PubMed
    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. - PMC - PubMed
    1. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. - PubMed
    1. Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675–1684. - PMC - PubMed
    1. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544–551. - PubMed

Publication types